SCHEMBL13656111

SCHEMBL13656111

COOSNc1ccc(OCC(=O)NCCNc2ccc(Cl)c(Cl)c2)cc1

nearest known ligand 0.67

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
GRIN1 Q05586 8/20 0.67
GRIN2B Q13224 8/20 0.67
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
ALDH1A1 P00352 2/20 0.46
HTT P42858 2/20 0.45
MAPT P10636 1/20 0.45
MAPK1 P28482 1/20 0.45
KCNH2 Q12809 2/20 0.44
TAOK1 Q7L7X3 1/20 0.41
TAOK3 Q9H2K8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13656132 0.87 GRIN1 (0.67) GRIN1GRIN2BALDH1A1
SCHEMBL13656202 0.86 GRIN1 (0.49) GRIN1GRIN2BMEN1KMT2AALDH1A1
SCHEMBL13656207 0.85 GRIN1 (0.69) GRIN1GRIN2BALDH1A1HTTTAOK1
SCHEMBL13656203 0.85 GRIN1 (0.71) GRIN1GRIN2BMEN1KMT2AALDH1A1
SCHEMBL13656204 0.84 GRIN1 (0.64) GRIN1GRIN2BKMT2AMAPTKCNH2
SCHEMBL2020386 0.83 GRIN1 (0.73) GRIN1GRIN2BMEN1KMT2AALDH1A1
SCHEMBL7997181 0.82 GRIN1 (0.72) GRIN1GRIN2BMEN1KMT2AALDH1A1
SCHEMBL2018740 0.81 GRIN1 (1.00) GRIN1GRIN2BMEN1KMT2AALDH1A1
SCHEMBL13656108 0.80 GRIN1 (0.64) GRIN1GRIN2BALDH1A1KCNH2
SCHEMBL13656130 0.80 GRIN1 (0.69) GRIN1GRIN2BMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420680-B2 NMDA receptor antagonists for neuroprotection EMORY UNIVERSITY (US) 2013-04-16 US disclosed
US-20090253710-A1 NMDA Receptor Antagonists for Neuroprotection EMORY UNIVERSITY 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253710-A1 NMDA Receptor Antagonists for Neuroprotection GRIN1, GRIN2C, GRIK1 GRIN1 1/4885GRIN2B 7/4885MEN1 3672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.